Effect of granulocyte colony-stimulating factor mobilization on phenotypical and functional properties of immune cells

Experimental Hematology

Volumn 29, Issue 4, 2001, Pages 458-470

  Tayebi, Hakim ^a   Kuttler, Fabien ^a   Saas, Philippe ^a   Lienard, Agnès ^a   Petracca, Bruno ^a   Lapierre, Valérie ^b   Ferrand, Christophe ^a   Fest, Thierry ^c   Cahn, Jean Yves ^c   Blaise, Didier ^d   Kuentz, Mathieu ^e   Hervé, Patrick ^a   Tiberghien, Pierre ^a   Robinet, Eric ^a,f  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^d INSTITUT PAOLI CALMETTES   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f Culaire Etablissement Fran Ais du Sang Bourgogne/Franche Comt   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CELL SURFACE MARKER; CYTOKINE; FAS ANTIGEN; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; MESSENGER RNA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CELL FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMETRY; DONOR; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOCYTOCHEMISTRY; LYMPHOCYTE; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MOBILIZATION; MULTICENTER STUDY; NATURAL KILLER CELL; PERIPHERAL BLOOD STEM CELL; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIBONUCLEASE PROTECTION ASSAY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD45; ANTIGENS, CD95; B-LYMPHOCYTES; BLOOD DONORS; BONE MARROW TRANSPLANTATION; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA-DR ANTIGENS; HUMANS; IMMUNOPHENOTYPING; INTERFERON TYPE II; INTERLEUKIN-13; INTERLEUKIN-2; INTERLEUKIN-4; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; PHENOTYPE; RECEPTORS, INTERLEUKIN-2; RNA, MESSENGER; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TISSUE DONORS; TUMOR NECROSIS FACTOR-ALPHA;

TRIXIS;

EID: 0035071414     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(01)00613-0     Document Type: Article

References (76)

1. T cell subsets and graft-versus-host disease
2. Graft-versus-leukemia reactions after bone-marrow transplantation
3. Impact of T-cell depletion on outcome of allogeneic bone marrow transplantation for standard risk leukemias
4. Recombinant human granulocyte colony-stimulating factor can mobilize sufficient amounts of peripheral blood stem cells in healthy volunteers for allogeneic transplantation
5. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia; a report from the Societé Française de Greffe de Moelle
6. Allogeneic blood cell transplants for hematological malignancy; preliminary comparison of outcomes with bone marrow transplantation
7. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma; potential advantage of blood over marrow graft
8. Peripheral blood vs bone marrow as source for allogeneic hematopoietic stem cell transplantation
9. Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation
10. Lymphocyte content in peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor
11. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation; safety, kinetics of mobilization, and composition of the graft
12. Detection of intracellular cytokines in citrated-whole blood or marrow samples by flow cytometry
13. Single step method of RNA isolation by acid-guanidium thiocyanate-phenol-chloroform extraction
14. + cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells
15. Granulocyte colony-stimulating factor downregulates allogeneic immune responses by posttranscriptional inhibition of Tumor Necrosis Factor-α production
16. +) in the blood of normal donors
17. T-cell subsets and suppressor cells in human bone marrow
18. - T cells
19. Characteristics of T-cell receptor Vα24JαQ T cells, a human counterpart of murine NK1 T cells, from normal subjects
20. + cells in normal, healthy individuals with human cytomegalovirus (HCMV) carrier status, phenotypic and functional analyses
21. Natural killer (NK) cells are functionally abnormal and NK cell progenitors are diminished in granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cell collection
22. + T cells
23. IL-12-induced up-regulation of NKRP1A expression in human NK cells and consequent NKRP1A-mediated down-regulation of NK cell activation
24. Human NKRP1A. A disulphide-linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes
25. CD161 (human NKR-P1A) Workshop panel report
26. + T cells upon NKR-P1A cross-linking
27. The human leucocyte antigen (HLA)-C-specific 'activatory' or 'inhibitory' natural killer cell receptors display high homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions
28. NKR-P1A is a target-specific receptor that activates natural killer cell cytotoxicity
29. Regulation of T cell lymphokine production by killer cell inhibitory receptor recognition of self HLA class I allelles
30. Natural killer (NK) T cells are significantly decreased in the peripheral blood of patients with rheumatoid arthritis (RA)
31. Differential regulation of killer cell Ig-like receptors and CD94 lectin-like dimers on NK and T lymphocytes from HIV-1-infected individuals
32. rhG-CSF in healthy donors; mobilization of peripheral hemopoietic progenitors and effect on peripheral blood leucocytes
33. Inhibition of lymphocyte blastogenic response in healthy donors treated with recombinant human granulocyte colony-stimulating factor (rhG-CSF); possible role of lactoferrin and interleukin-1 receptor antagonist
34. Effet of filgrastim treatment on inflammatory cytokines and lymphocyte functions
35. Alloantigen presenting capacity, T cell alloreactivity and NK function of G-CSF-mobilized peripheral blood cells
36. - T cells
37. Allogeneic peripheral blood stem cell transplantation results in weaker alterations of early T-cell compartment homeostasis than bone marrow transplantation
38. Allogeneic peripheral blood stem cell transplantation for hematological malignancies-an analysis of kinetics of engraftment and GVHD risk
39. Allogeneic peripheral blood progenitor cell transplantation; analysis of short-term engraftment and acute GVHD incidence in 33 cases
40. High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies
41. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease
42. Immune reconstitution after bone marrow transplantation for combined immunodeficiencies; down-modulation of bcl-2 and high expression of CD95/Fas account for increased susceptibility to spontaneous and activation-induced lymphocyte cell death
43. Peripheral blood T cells generated after allogeneic bone marrow transplantation; lower levels of bcl-2 protein and enhanced sensitivity to spontaneous and CD95-mediated apoptosis in vitro
44. Apoptosis of peripheral blood T lymphocytes early and late after bone marrow transplantation
45. γ interferon induces fas-dependent apoptosis of Peyer's patch T cells in mice following peroral infection with Toxoplasma gondii.
46. Cross-linking of CD4 molecules upregulates Fas antigen expression in lymphocytes by inducing interferon-γ and tumor necrosis factor-α secretion
47. + T cell activation and IFN-γ production
48. Cytokine cascades in acute graft-versus-host disease
49. Differential ability of Th1 and Th2 cells to express Fas ligand and to undergo activation-induced cell death
50. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease
51. Allogeneic peripheral blood progenitor cell transplantation in a murine model; evidence for an improved graft-versus-leukemia effect
52. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease; impact on blood progenitor cell transplantation
53. Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products; a mechanism for monocyte-mediated suppression of T-cell proliferation
54. Detection of intracellular cytokines by flow cytometry
55. Effect of G-CSF mobilization on type 1 and type 2 T cells and correlation to acute graft-versus-host disease (GVHD)
56. G-CSF reduces IFN-γ and IL-4 production by T cells after allogeneic stimulation by indirectly modulating monocyte function
57. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo
58. Suppression of alloreactive T-cell responses, after in vivo G-CSF treatment, is mediated by IL-10 and TGF-β and it is associated with a switch toward a Th2 phenotype
59. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-β1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients
60. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
61. Impaired induction of the CD28-responsive complex in granulocyte colony-stimulating factor mobilized CD4 T cells
62. Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers
63. Immunoregulatory cytokines in bone marrow and peripheral blood stem cell products
64. IL-2 expansion of T and NK cells from growth factor-mobilized peripheral blood stem cell products
65. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells
66. Comparison of monocyte-dependent T cell inhibitory activity in GM-CSF vs G-CSF mobolized PSC products
67. + T cells reciprocally regulate acute graft versus host disease
68. - αβ bone marrow T cells with suppressor activity
69. + subpopulations
70. + natural killer T-cell cytotoxic activity; an important immune regulatory function
71. Expression of killer inhibitory receptors on cytotoxic cells from HIV-1-infected individuals
72. Regulation of KIR expression in human T cells; a safety mechanism that may impair protective T-cell responses
73. Interleukin-15-induced maturation of human natural killer cells from early thymic precursors; selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor
74. + T lymphocytes
75. Transforming growth factor-β-induced expression of CD94/NKG2-A inhibitory receptors in human T lymphocytes
76. Natural killer cell activation and inhibition by receptors for MHC class I